Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies

Ruth Katz's Biography

Ruth Katz, Professor of Pathology, Chief Image Analysis Laboratory, Chief Research Cytopathology, MD Anderson Cancer Center

RUTH L. KATZ, MD is a board certified Anatomic Pathologist and Cytopathologist who is currently Professor of Pathology, Chief of Research Cytopathology, and Director, Image Cytometry Diagnostic Laboratory at The University of Texas MD Anderson Cancer Center, Houston, Texas. Besides her clinical responsibilities, her major research interest is in looking at genetic susceptibility to develop lung cancer, and she has developed a panel of novel molecular markers in sputum that are designed to predict those people at high risk for developing lung cancer. This test is currently under study for FDA approval in the USA, and was recently licensed to the largest laboratory in China, Hong Kong and Taiwan by the Bioview Company. It also recently received the CE mark for European countries. Currently she is working on developing a FISH assay to detect circulating tumor cells in the blood of lung cancer patients. She is the holder of several patents pertinent to her discoveries.. She is active in numerous national and international associations including the American Society of Cytopathology, International Academy of Cytology, European Congress of Pathology, USCAP, and the American Association for Cancer Research. She is a well-known Cytopathology lecturer and workshop leader both nationally and internationally. She has authored and co-authored over 200 articles in leading peer review journals including: The New England Journal of Medicine, American Journal of Clinical Pathology, Acta Cytologica, Diagnostic Cytopathology, Cancer, Clinical Cancer Research, and Journal of the National Cancer Institute.

Ruth Katz Image

Detection of Circulating Tumor Cells…What is the Gold Standard and is There One?

Tuesday, 28 October 2014 at 09:45

Add to Calendar ▼2014-10-28 09:45:002014-10-28 10:45:00Europe/LondonDetection of Circulating Tumor Cells…What is the Gold Standard and is There One?

The  FDA approved technology for CTCs relies on the expression of EpCAM, however, this current assay cannot account for the phenomenon of lineage plasticity or epithelial-mesenchymal transition (EMT) which in turn endows CTCs with stem-cell capabilities and the ability to ultimately initiate macro- metastases by mesenchymal –epithelial transition (MET).  Genetic heterogeneity in the context of CTCs will be discussed including automated FISH-based assays for detecting CTCs of different subtypes, including stem cells, mesenchymal and epithelial cells, that simultaneously analyze specific immunohistochemical phenotypes together with  genomic instability within the same cell. Using this technology on sequential bloods in patients with early lung cancer, both at base- line and post -surgery, we were able to prospectively follow the phenotypic changes in CTCs. Using an antigen independent assay to analyze  genetic markers in peripheral blood mononuclear cells by FISH in patients at risk for lung cancer or with early lung cancer,we have shown a high degree of accuracy to predict the presence of lung cancer in patients versus control subjects.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid